High‐dose DDAVP intranasal spray (Stimate®) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A

C. Leissinger,D. Becton,C. Cornell,J. Gill

DOI: https://doi.org/10.1046/j.1365-2516.2001.00500.x

2001-05-01

Haemophilia

Abstract:An open‐label multicentre trial was conducted to evaluate high‐dose DDAVP (desmopressin acetate) intranasal spray (Stimate®; 1.5 mg mL–1), for the control of bleeding in 333 patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease, or symptomatic carriers of haemophilia A. Overall, 278 patients received 2170 doses of high‐dose DDAVP intranasal spray (1.5 mg mL–1). Using study‐defined guidelines, patients evaluated the efficacy of high‐dose DDAVP intranasal spray (1.5 mg mL–1) as ‘excellent’ or ‘good’ in 743 (95%) of 784 bleeding episodes. It demonstrated ‘excellent’ results in 384 (93%) of 413 administrations for prophylaxis and in eight of eight uses prior to acute surgical or dental procedures. When used for the treatment of menorrhagia, the efficacy of high‐dose DDAVP intranasal spray (1.5 mg mL–1) was rated as ‘excellent’ after 655 (92%) of 721 daily uses. Of 2170 doses of high‐dose DDAVP intranasal spray (1.5 mg mL–1), 172 (8%) were associated with adverse events. A total of 272 adverse events were reported among 80 patients. Of these, 239 (88%) were mild or moderate in intensity and only one patient was removed from the study due to an adverse event. These results demonstrate the safety and efficacy of high‐dose DDAVP intranasal spray (1.5 mg mL–1) for control of bleeding episodes in patients with mildly decreased levels of factor VIII, von Willebrand factor, or both.